| Ytd | 56.94% | |
| 1y | 182.50% |
| Open | 15.36 | Prev Close | 15.50 | Low | 14.92 | High | 15.51 | Mkt Cap | 1.44B |
| Vol | 458.67K | Avg Vol | 4.98M | EPS | -3.15 | P/E | N/A | Forward P/E | -7.61 |
| Beta | 0.88 | Short Ratio | 3.43 | Inst. Own | 104.19% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 11.81 | 200-d Avg | 8.43 | 1yr Est | 19.50 |
REPL News
Important Information Regarding Section 20(a) Individual Liability Claims: CEO Sushil Patel and CFO
LOS ANGELES, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shar
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been
NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recogni
Investors allege Replimune Group, Inc. built its RP1 regulatory strategy around single-arm trial des
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law
Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your
LOS ANGELES, Aug. 27, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national sharehol
LOS ANGELES, Aug. 27, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action law
Investors allege Replimune Group, Inc. supported its RP1 biologics license resubmission with data fr
JP Morgan analyst Anupam Rama maintains Replimune Group (NASDAQ:REPL) with a Overweight and raise
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has
LOS ANGELES, Aug. 25, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investor
Robbins LLP is Investigating Allegations that Replimune Group, Inc. Misled Investors Regarding the E
LOS ANGELES, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shar
LOS ANGELES, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors o
NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recogni
Investors allege Replimune Group, Inc. told the market its RP1 resubmission was a complete response
SAN DIEGO, Aug. 21, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors t
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered L
LOS ANGELES, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shar
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.72) per share which beat the analyst
The aggregate gross proceeds from the offering are expected to be approximately $150 million, before
Wedbush analyst Robert Driscoll upgrades Replimune Group (NASDAQ:REPL) from Neutral to Outperform
FDA grants Replimune accelerated approval for TUDRIQEV in combination with nivolumab to treat advanc
Replimune Group, Inc. (NASDAQ:REPL), a commercial stage biotechnology company pioneering the develop
Analysts upgraded Replimune, Madrigal, BBB Foods, Palantir, and Fomento Economico. See other opinion
Leerink Partners analyst Jonathan Chang upgrades Replimune Group (NASDAQ:REPL) from Market Perfor
Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular sessio
FDA advisory panel backed Replimune's RP1 melanoma data ahead of the agency's August 2 decis
US stocks rise, Nasdaq up 300 points. Dow up 0.36%, Nasdaq up 1.31%, S&P 500 up 0.65%. Amazon sh
Wedbush analyst Robert Driscoll maintains Replimune Group (NASDAQ:REPL) with a Neutral and raises
Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-
Top Wall Street analysts upgraded IP, AXTI, REPL, and PLXS stocks with higher price targets. See wha
AMZN: 13% | Amazon.com shares are trading higher after the company reported better-than-expected Q2
Amazon reported strong Q2 results, beating revenue and earnings estimates. Shares jumped 11.9% in pr
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-panel-backs-replimune-skin-cancer
Replimune shares fall after FDA briefing documents questioned RP1 trial data for advanced melanoma a
Gainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular se
Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-
Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Cana
Wedbush analyst Robert Driscoll maintains Replimune Group (NASDAQ:REPL) with a Neutral and raises
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.76) per share which missed the analys
Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its D
Replimune Group, Inc. (NASDAQ:REPL), a clinical-stage biotechnology company pioneering the developme
FDA reverses its rejection of Regenxbio Navsunli, allowing the company to refile its gene therapy ap
Several stocks, including Optimum Communications Services, surged while Dow fell. Technology, energy
Replimune Group (REPL) shares gain on key RP2 & RP1 oncology data presentations at ASCO. Read th